Literature DB >> 3585505

Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison.

J Bomanji, D A Levison, W D Flatman, T Horne, P M Bouloux, G Ross, K E Britton, G M Besser.   

Abstract

The percentage uptake of [123I]metaiodobenzylguanidine (MIBG) by tumors of the paraganglion system is compared with the number of neurosecretory granules (assessed by both light and electron microscopy) in the subsequently resected tumors in six patients. Iodine-123 MIBG was injected intravenously; the tumor uptake of [123I]MIBG varied between 0.001% and 0.14% of the injected dose per gram of tumor tissue at 22 hr. The number of neurosecretory granules in tissue sections was scored on a scale of I-III. A direct proportional correlation was found between the percentage uptake of [123I]MIBG by the tumor and the number of neurosecretory granules in the tissue sections but not with plasma or urinary catecholamines. This technique for imaging reflects the storage status of the tumor better than plasma and urinary catecholamine measurements.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3585505

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  24 in total

1.  False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.

Authors:  Jay S Fonte; Jeremyjones F Robles; Clara C Chen; James Reynolds; Millie Whatley; Alexander Ling; Leilani B Mercado-Asis; Karen T Adams; Victoria Martucci; Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2012-02-13       Impact factor: 5.678

2.  Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.

Authors:  Lucia Martiniova; Shiromi M Perera; Frederieke M Brouwers; Salvatore Alesci; Mones Abu-Asab; Amanda F Marvelle; Dale O Kiesewetter; David Thomasson; John C Morris; Richard Kvetnansky; Arthur S Tischler; James C Reynolds; Antonio Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

Review 3.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

Review 4.  ⁶⁸Ga-labelled peptides in the management of neuroectodermal tumours.

Authors:  Meeran Naji; Adil AL-Nahhas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 5.  A case of (123)I-MIBG scintigram-negative functioning pheochromocytoma: immunohistochemical and molecular analysis with review of literature.

Authors:  Aiko Kurisaki-Arakawa; Tsuyoshi Saito; Michiko Takahashi; Keiko Mitani; Takashi Yao
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 6.  The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature.

Authors:  Alireza Mojtahedi; Sanjay Thamake; Izabela Tworowska; David Ranganathan; Ebrahim S Delpassand
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-08-15

7.  Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells.

Authors:  Yanlin Zhao; Xiao Zhong; Xiaohong Ou; Huawei Cai; Xiaoai Wu; Rui Huang
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

Review 8.  Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry.

Authors:  A R Wafelman; C A Hoefnagel; R A Maes; J H Beijnen
Journal:  Eur J Nucl Med       Date:  1994-06

Review 9.  Norepinephrine Transporter as a Target for Imaging and Therapy.

Authors:  Neeta Pandit-Taskar; Shakeel Modak
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

Review 10.  Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities.

Authors:  A P van Gils; A R van Erkel; T H Falke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.